



Regulation of Keap1-Nrf2 Signaling in Health and Diseases

Guest Editors:

Dr. Gobinath Shanmugam

Division of Cardiovascular
Diseases, Department of
Medicine, The University of
Alabama at Birmingham,
Birmingham, AL, USA

**Dr. Kishore Kumar S.
Narasimhan**

Department of Pharmacology
and Neurosciences, Creighton
University, 2500 California Plaza,
Omaha, NE, USA

Deadline for manuscript
submissions:

closed (30 June 2023)

Message from the Guest Editors

In this Special Issue, we invite researchers worldwide to submit original research articles, brief reports and review articles that describe the role of Nrf2 signaling in redox metabolism; cardiac function and diseases including myocardial infarction, hypertrophy, atherosclerosis, etc.; neuronal function and diseases including neurodegenerative diseases, neurodevelopmental disorders, neuroplasticity and synaptic transmission, neuropathic pain, etc.; various cancer pathologies and metabolic disorders including diabetes and obesity, inflammation, etc. In addition, we welcome articles that investigate potential natural or synthetic compounds that can activate/deactivate Nrf2-signaling, thereby preventing/leading to the progression of these diseases.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)